Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214878 | 0.76 | MAPK8 (0.41) | RET | |
| SCHEMBL214404 | 0.75 | ATM (0.31) | — | |
| SCHEMBL214660 | 0.72 | SIK1 (0.33) | CDK2CCNA2CCNA1 | |
| SCHEMBL2735393 | 0.72 | CCNA2 (0.54) | CDK2CCNA2CCNA1 | |
| SCHEMBL4104868 | 0.71 | RAB9A (0.37) | — | |
| SCHEMBL215407 | 0.70 | MTOR (0.38) | — | |
| SCHEMBL214864 | 0.70 | JAK2 (0.32) | — | |
| SCHEMBL215228 | 0.70 | SCN9A (0.44) | — | |
| SCHEMBL213884 | 0.70 | HCAR1 (0.33) | — | |
| SCHEMBL5867924 | 0.70 | CCNA2 (1.00) | CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | CDK2 67/4885CCNA2 776/4885CCNA1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.